

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231*Els*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/162,648 09/29/98 HISERODT

J

023601  
CAMPBELL & FLORES LLP  
4370 LA JOLLA VILLAGE DRIVE  
7TH FLOOR  
SAN DIEGO CA 92122

HM12/0929

EXAMINER

STROUP, C

ART UNIT	PAPER NUMBER
----------	--------------

1633

DATE MAILED:

09/29/00

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks**

## Office Action Summary

Application No. 09/162,648	Applicant(s) Hiserodt JC
Examiner Stroup, Carrie	Group Art Unit 1633

Responsive to communication(s) filed on Jun 20, 2000

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle 835 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

### Disposition of Claim

Claim(s) 1-20 is/are pending in the application.  
Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

Claim(s) \_\_\_\_\_ is/are allowed.

Claim(s) 1-20 is/are rejected.

Claim(s) \_\_\_\_\_ is/are objected to.

Claims \_\_\_\_\_ are subject to restriction or election requirement.

### Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

The proposed drawing correction, filed on \_\_\_\_\_ is  approved  disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All  Some\*  None of the CERTIFIED copies of the priority documents have been received.

received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

### Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). 8

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES --

Art Unit: 1633

## DETAILED ACTION

Applicant's amendment Paper 9, filed 6/20/00, has been entered. Claims 10, 16, 19, and 20 have been amended. Claims 1-20 are currently pending in the present application.

### ***Claim Rejections - 35 USC § 102***

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 1-10, 12-16, and 18-20 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Granger (US Patent 5,837,233).

Applicant's claimed invention is to a method for treating cancer or eliciting an anti-cancer response in a human patient suffering from melanoma, pancreatic, liver, colon, prostate, or breast cancer, and a pharmaceutical composition, comprising implanting at or around the tumor site a first cell population containing alloactivate lymphocytes that are allogeneic to leukocytes in the patient and comprising about  $2 \times 10^9$ - $2 \times 10^{10}$  donor PBMC and  $1 \times 10^8$ - $2 \times 10^9$  patient or 2nd donor PMBC's, wherein said implantation is repeated within an interval of at least three days, one to eight weeks, or two to twelve months (claims 1, 7, 8, 11, 12, 18). Said cell populations are obtained by a

Art Unit: 1633

process in which donor lymphocytes are alloactivated by coculturing *ex vivo* with stimulator leukocytes for a period of about 48-72 hours, or are obtained by a process in which donor lymphocytes are alloactivated by coculturing *ex vivo* with stimulator leukocytes and harvested at about the time of initial alloactivation, via acridine orange or CD69 assay (claims 11, 17). The first implantation stimulates a response, such as an inflammatory or immunological response, against the tumor prior to the second implantation, and wherein said lymphocytes are activated against leukocytes of the patient or of a third-party donor (claims 2-6). Said methods also include a pharmaceutical composition comprising alloactivated lymphocytes allogeneic to leukocytes in a cancer patient packaged with written information for the treatment of the patient (claims 19, 20).

Granger et al teach a method for treating cancer, such as melanoma, pancreatic, liver, colon, prostate, and breast cancer (claim 37), in a human patient comprising implanting at or around the site of a tumor a cell population of about  $2*10^9$ - $6*10^9$  cells and comprising alloactivated human donor lymphocytes produced by coculturing said lymphocytes *ex vivo* with leukocytes from said patient at a ratio of 10:1 to 20:1 donor: patient cell ratio, for at least 48 hours, and preferably 1-5 days (claim 37; col 7, lines 30-50). Treatment results in the patient generating a therapeutic or immunologic response against tumor growth and transplanted lymphocytes up to 74 weeks post implant (col 4, lines 1-35; claims 1-37). Granger et al also teach the use of a pharmaceutical composition comprising a sterile vial containing a unit dosage of mixed lymphocyte culture (a mixture of live alloactivated donor and patient lymphocytes) and bearing a label which sets forth information concerning the pharmaceutical use of the composition in treating a tumor in a human (col 6, lines 8-16).

Applicants state in Paper 9, filed 6/20/00, page 7, that Granger et al teach away from administering two dose wherein two patients showed progressive reduction in tumor mass over periods of 58 and 74 weeks, respectively. The Office is at a loss as to comprehending how the successful response of two patients to one dose dissuades the artisan from administering a second dose. It is a common practice within the cancer therapy field that when the efficacy of a

Art Unit: 1633

treatment begins to subside, then another treatment or dose is administered. Therefore, based on this common therapeutic practice and the disclosure of Granger, which the Applicant states in Paper 9, filed 6/20/00, page 6, is equivalent to the Applicant's claimed method with the exception that two dose are administered, then one of skill in the art would administer a second dose of alloactivated lymphocytes to the tumor site to prolong the efficacy and potency of the anti-tumor therapy.

It is noted that the Applicant's arguments in Paper 9, filed 6/20/00, page 10, stating that the specification discloses an unanticipated synergistic effect from the use of sequential administrations of alloactivated lymphocytes (specification, pg 11-12) has been found to not be persuasive in light of data from Granger (US Patent 5,837,233) and the declaration by Dr. T. Gatanaga. Granger et al teach that the longevity of patients receiving one administration varies from approximately 140 days to 350 days (see Figure 1), whereas Gatanaga et al teach that the administration of two doses of allogeneic cells provides approximately the same range. Additionally, Gatanaga et al fails to provide a statistical analysis comparing the longevity of patients receiving one dose versus those receiving two. In light of these facts, the applicant has not demonstrated that an unanticipated synergistic effect occurs upon administering two or more doses of alloactivated lymphocytes.

***Claim Rejections - 35 USC § 103***

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1633

4. Claims 11 and 17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Granger, GA (US Patent 5,837,233) as applied to claims 1-10, 12-16, and 18-20 above, and further in view of Feldhaus et al (US Patent 5,759,805) and Haugland, RP (1992).

Applicant's claimed invention further comprises the process wherein donor lymphocytes are alloactivated by coculturing ex vivo with stimulator leukocytes and harvested at about the time of initial alloactivation, measurable with acridine orange or CD69 assay.

Haugland RP teach that acridine orange is a fluorescent dye utilized for assessing cell functions, such as metabolic processes (pg 172-173).

Jung et al teach that CD69 is an antigen on human lymphocytes expressed during the early stages of cell activation(abstract).

In light of Granger GA, Jung et al, and Haugland, it would have been obvious to one of ordinary skill in the art to determine the point of initial alloactivation via acridine orange or CD69 assays because they were routine in the art in studying cellular metabolic processes (Haugland, pg 173) and that CD69 expression is specific to early stage activated lymphocytes (Jung et al, abstract).

No claim is allowed.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carrie Stroup whose telephone number is (703) 306-5439. The examiner can normally be reached on Monday through Friday from 8:30 AM to 6:00 PM.

Art Unit: 1633

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John Leguyader, can be reached at (703) 308-0447. The fax number for this Group is (703) 308-0294.

Carrie Stroup

  
DEBORAH J.R. CLARK  
PRIMARY EXAMINER